Navigation Links
IPO Rumor: Axium Pharmaceuticals
Date:8/15/2017

HIGH POINT, N.C., Aug. 15, 2017 /PRNewswire/ -- Axium Pharmaceuticals Inc., the creator of the drug Truveta for the treatment of epilepsy is rumored to be in the beginning stages of an IPO.

The United States spends approximately $15.5 billion annually on epilepsy medications with the average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month supply.

AXIUM PHARMACEUTICALS, INC
AXIUM PHARMACEUTICALS, INC

Another staggering figure is the fact that Americans spent $42 billion on anxiety medications last year alone.

Anxiety Disorders affect 18.1 percent of adults in the United States; that's approximately 40 million adults between the age of 18 to 54. This equates to one-third of the $148 billion total mental health bill for the U.S.

Anyone can clearly see the potential as an investor in Axium Pharmaceuticals Inc. for profitability.

"We believe that investing in Axium Pharmaceuticals Inc. will be like investing in the largest pharmaceutical companies in the world when they were first getting started right before their stock exploded," says Dr. Anthony Harrelson, CEO.

Axium Pharmaceuticals Inc. plans to trade their stock on the OTC Markets Group quotation system.

Buying Axium stock presents an excellent entry point for investors willing to take a risk and develop this industry, which is undergoing rapid, positive changes.

Axium has challenged themselves to be the innovators in the treatment of epilepsy and anxiety. Axium is a leader in biotechnology and pharmaceutical research as well as in the development and production of their advances. Axium is on the cutting edge of development in their field and in proposed clinical trials of new pharmaceutical products and devices, up to and including FDA approval.

Axium strongly believes health and happiness are their business. Axium continuously strives to make life a better, happier and healthier experience with their cutting edge, innovative products.

Axium's prime goal is to come up with newer, simpler, and safer solutions that are more effective.

Axium is heavily interested and invested in the research and development of ground breaking products and technology that are more adapted to the complex demands of today's world and the ever-growing challenges of tomorrow.

"Axium delivers a better present for all today," says Dr. Harrelson.

Axium is not just on the forefront of development, they are at the forefront of access and clinical trials of new pharmaceutical products and devices, up to and including FDA approval.

"The future has a lot to offer and Axium is the future today," Dr. Harrelson adds.

AXIUM PHARMACEUTICALS INC.
265 Eastchester Dr. Suite 133, # 201
High Point, NC, 27262
www.axium-pharma.com
www.axium-pharma.com/investors
Tel: 1-888-805-7734

Disclaimer: This information is available for information purposes only and does not constitute an offer or sale or any form of general solicitation or general advertising of interests in any investment and or investment vehicle. Any such offer will only be made in compliance with applicable state and federal securities laws pursuant to an offering. This communication shall not constitute an offer to sell or the solicitation of an offer to buy securities nor shall there be any sale of these securities in any state in which such solicitation or sale would be unlawful prior to registration or qualification of these securities under the laws of any such state.

Related Images

image1.jpg

image2.jpg

image3.jpg

Related Links

Axium

INVESTOR RELATIONS

View original content with multimedia:http://www.prnewswire.com/news-releases/ipo-rumor-axium-pharmaceuticals-300504742.html


'/>"/>
SOURCE Axium Pharmaceuticals, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
2. Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeants Board of Directors
3. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
4. Access Pharmaceuticals Reports First Quarter Results
5. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
6. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
7. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
8. Aveo Pharmaceuticals, Inc. Sued by Investor
9. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm
10. Atlantic Pharmaceuticals President Named Health Care Hero Finalist in Atlanta Business Chronicle for Drug Abuse Deterrent Technology
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) ... developed an innovative way to use nonlinear optical imaging ... of new drugs. ... Conference will show how researchers from BioPharmX and the ... School used a suite of imaging techniques in what ...
(Date:10/10/2017)...  NDS received FDA 510(k) clearance in May 2017 for its ... specifically designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... to support the improvement of patient outcomes, procedural efficiency, and the ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology:
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts ... Washington, D.C., for the 49th Congress of the International Society of Paediatric Oncology ... of the Center for Cancer and Blood Disorders at Children’s National, and ...
(Date:10/12/2017)... ... , ... Health Literacy Innovations (HLI), creator of the Health ... Cancer Patient Education Network (CPEN), an independent professional organization that shares best practices ... , As CPEN’s strategic partner, HLI will help support CPEN members by ...
Breaking Medicine News(10 mins):